Avacta

Avacta will deliver two presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from 17 April 2026 to 22 April 2026 in San Diego, California, USA. avacta.com/avacta-announc… #AVCT

Avacta today announces the opening of the Phase 1 trial of FAP-Exd (AVA6103), the Company’s second clinical program and the first sustained-release pre|CISION® peptide drug conjugate. avacta.com/avacta-announc… #AVCT

The webcast and slides from CEO Christina Coughlin and CFO Brian Hahn's presentation at the 46th Annual TD Cowen Health Care Conference in Boston can be accessed here: avacta.com/events-present… #AVCT

Part 2 of the Avacta Academy podcast series is out now, with CEO Chris Coughlin and CMO David Liebowitz looking at how to initiate a clinical trial with a new drug candidate. #AVCT #Biotech #Cancer #DrugDevelopment avacta.wistia.com/medias/6s5zo87…

Investors interested in accessing the presentation may view the replay of the presentation, which will be available after the event on the Investor Resources page of the Avacta website. #AVCT

Avacta CEO Christina Coughlin and CFO Brian Hahn will be in Boston this week for the 46th Annual TD Cowen Health Care Conference in Boston. The company will host investor meetings throughout the day on March 4, with a live presentation at 9:50 AM ET. #AVCT

Our Principal Medicinal Chemist Ellen Watts presented at @CDDVault's European Life Science Community Meeting yesterday. Ellen discussed the progress of the pre|CISION platform and development of our sustained release pipeline asset AVA6103. #AVCT

Watch episode 14 of the Avacta R&D Spotlight Series, where the team discuss new data released today demonstrating the advantages of the proprietary pre|CISION platform, compared to a marketed antibody drug conjugate (ADC). avacta.wistia.com/medias/az3tqty… #AVCT

Avacta has today published new data which demonstrates the more favorable delivery and advantages of the proprietary pre|CISION platform, compared to a marketed antibody drug conjugate (ADC). avacta.com/avactas-precis… #AVCT

Christina Coughlin and Brian Hahn will participate in the 46th Annual TD Cowen Health Care Conference in Boston on March 3, 2026.  A live Company presentation will be available after the event. #AVCT avacta.com/avacta-to-part…

In episode one, Avacta’s management team breaks down all the work that goes into an IND, and why it’s an important milestone on the way to reaching patients with a new drug. #AVCT avacta.wistia.com/medias/w8k1mnx…

We're proud to lauch our new podcast series - Avacta Academy: The Nuts and Bolts of Drug Development Explained.  Want to learn more about how the business of drug development actually works? Join us for a fascinating look at the key steps on the pathway from idea to a drug. #AVCT

We are delighted to announce the appointment of chemistry expert Francis Wilson as our new Chief Scientific Officer. The appointment provides further impetus to Avacta, as we advance our innovative, tumor-targeted therapies to patients in need. avacta.com/avacta-appoint… #AVCT

Avacta has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program. avacta.com/avacta-announc… #AVCT

Our 2nd pre|CISION medicine is heading to the clinic! With FDA clearance of the IND for AVA6103, we’re one step closer to a new approach for cancer treatment. We’re honored to have Dr. Alexander Spira and team joining us on this journey. Phase 1 begins later this quarter. #AVCT

Avacta is pleased to announce U.S. FDA clearance of the IND application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan. avacta.com/avacta-announc… #AVCT

Avacta has published a trading update for the year ended December 31, 2025. avacta.com/year-end-tradi… #AVCT

Avacta announces the appointment of Strand Hanson Limited as the Company’s Nominated Adviser, with immediate effect. avacta.com/appointment-of… #AVCT

We’re excited to join the biotech community in San Francisco with the JP Morgan Healthcare Conference & Bio Showcase 2026 happening next week. We look forward to seeing you there. #JPM26 #Biotech #AVCT

In Episode 13 of the R&D Spotlight series, the team dive into FAP-Exd (AVA6103) and look under the hood of the sustained release mechnism. avacta.wistia.com/medias/thz9au7… #AVCT